Anatoly I. Ulyanin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anatoly I. Ulyanin has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Elena A. Poluektova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
18 shared publications - Vladimir Trofimovich Ivashkin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
17 shared publications - Oleg S. Shifrin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
14 shared publications - Roman Maslennikov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
11 shared publications - Vladislav Vladimirovich Tsukanov
Research Institute of Medical Problems of the North — Affiliated Branch of the Federal Research Center “Krasnoyarsk Science Center” of the Siberian Branch of the Russian Academy of Sciences
10 shared publications - Aleksandr S. Trukhmanov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
9 shared publications
Latest Publications
- 21 May 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (2)
The Combination of Anxiety and Depressive Disorders in Patients with Irritable Bowel Syndrome (Literature Review and Expert Council Resolution)
Aim : to review current understanding of the role of intestinal microbiota in the pathogenesis of irritable bowel syndrome (IBS), anxiety and depressive disorders, and to present the materials of the Expert Council, which met on April 19, 2025, in Moscow. Key points. A likely unifying factor in the development of IBS, anxiety, and depressive disorders is a change in the composition of the intestinal microbiota, which causes disruption of neuroendocrine, immune, and metabolic signaling pathways of interaction between the gut and brain (components of the gut-brain axis). The intestinal microbiota plays a coordinating role in maintaining the physiological constancy of these pathways. However, when its composition is disrupted, pathogenic mechanisms are activated, leading to the combined development of both IBS and anxiety and depressive disorders. Recent data have shown that patients with IBS, as well as those suffering from anxiety and depressive disorders, exhibit a unidirectional change in the composition of the intestinal microbiota, characterized by a decrease in the number of Bifidobacterium bacteria , suggesting their key role in the pathogenesis of these diseases. A pathogenetically substantiated therapeutic strategy for the combination of IBS and mental disorders includes modifying the gut microbiota using strain-specific pro biotics containing Bifidobacterium type species. Bifidobacterium longum 35624 and Bifidobacterium longum 1714 strains have demonstrated clinical efficacy in reducing the severity of IBS symptoms, anxiety, and depression. Conclusion . Prescribing a combination of Bifidobacterium longum 35624 and Bifidobacterium longum 1714 probiotic strains to patients with IBS, including those with comorbid mental disorders, is clinically justified. This combination of strains holds promise for inclusion in clinical guidelines for the management of patients with irritable bowel syndrome and mental and behavioral disorders.
- 21 May 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (2)
The Combination of Anxiety and Depressive Disorders in Patients with Irritable Bowel Syndrome (Literature Review and Expert Council Resolution)
Aim : to review current understanding of the role of intestinal microbiota in the pathogenesis of irritable bowel syndrome (IBS), anxiety and depressive disorders, and to present the materials of the Expert Council, which met on April 19, 2025, in Moscow. Key points. A likely unifying factor in the development of IBS, anxiety, and depressive disorders is a change in the composition of the intestinal microbiota, which causes disruption of neuroendocrine, immune, and metabolic signaling pathways of interaction between the gut and brain (components of the gut-brain axis). The intestinal microbiota plays a coordinating role in maintaining the physiological constancy of these pathways. However, when its composition is disrupted, pathogenic mechanisms are activated, leading to the combined development of both IBS and anxiety and depressive disorders. Recent data have shown that patients with IBS, as well as those suffering from anxiety and depressive disorders, exhibit a unidirectional change in the composition of the intestinal microbiota, characterized by a decrease in the number of Bifidobacterium bacteria , suggesting their key role in the pathogenesis of these diseases. A pathogenetically substantiated therapeutic strategy for the combination of IBS and mental disorders includes modifying the gut microbiota using strain-specific pro biotics containing Bifidobacterium type species. Bifidobacterium longum 35624 and Bifidobacterium longum 1714 strains have demonstrated clinical efficacy in reducing the severity of IBS symptoms, anxiety, and depression. Conclusion . Prescribing a combination of Bifidobacterium longum 35624 and Bifidobacterium longum 1714 probiotic strains to patients with IBS, including those with comorbid mental disorders, is clinically justified. This combination of strains holds promise for inclusion in clinical guidelines for the management of patients with irritable bowel syndrome and mental and behavioral disorders.
- 1 April 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (1)
Impact of Prucalopride and Multi-Strain Probiotic on Symptoms, Gut Microbiota Composition, Psychoemotional Status, Cognitive Function, and Quality of Life in Female Patients with Functional Constipation
Aim: to investigate the interrelationships between the severity of clinical symptoms, features of tryptophan metabolism, gut microbiota composition, quality of life, psychoemotional and cognitive status in female patients with functional constipation (FC), and to assess the ability of prucalopride as monotherapy and in combination with a multistrain probiotic to influence these parameters. Materials and methods. The study included 70 female patients with FC, who were randomized into two equal groups: patients of Group FC-P received prucalopride at a dose of 2 mg daily for 8 weeks, and patients of Group FC-PP received prucalopride at a similar dose together with a multi-strain probiotic ( Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus , not less than 1×10 9 CFU of each strain per capsule), 1 capsule 3 times a day for 8 weeks. At baseline, as well as after 2, 4, and 8 weeks, the groups were assessed for the number of defecations per week, stool form (Bristol Stool Scale, BSS), severity of abdominal bloating and abdominal pain against the background of bloating (Visual Analog Scale, VAS), as well as the presence of the need for additional straining, sensation of incomplete and difficult defecation. Before and after treatment, all subjects were assessed for levels of interleukin-1β, cortisol, brain-derived neurotrophic factor, tryptophan, kynurenine, kynurenic acid, serum and platelet serotonin, psychoemotional status (Spielberger — Hanin test, STAI), Hamilton Depression Rating Scale (HDRS), Four-Dimensional Symptom Questionnaire (4DSQ)), cognitive status (Brief Assessment of Cognition in Schizophrenia, BACS), quality of life (SF-36), and gut microbiota composition in stool samples (16S rRNA sequencing). Results. The study was completed by 34 patients in Group FC-P and 30 patients in Group FC-PP. Abdominal bloating directly correlated with the severity of somatization ( r = 0.25; p < 0.005) and inversely — with cortisol levels ( r = –0.29; p < 0.05). The severity of abdominal pain directly correlated with the levels of state and trait anxiety (STAI), distress, anxiety, and somatization (4DSQ) ( r = 0.32, p < 0.05; r = 0.28, p < 0.05; r = 0.31, p < 0.05; r = 0.26, p < 0.05; r = 0.35, p < 0.005, respectively) and inversely — with the indicators of vitality, emotional role functioning, and mental health (SF-36) ( r = –0.28, p < 0.05; r = –0.32, p < 0.01; r = –0.30, p < 0.05, respectively). Stool form type inversely correlated with the level of kynurenine ( r = –0.27; p < 0.05) and kynurenic acid ( r = –0.26; p < 0.05). The sensation of incomplete evacuation correlated with the severity of depression according to HDRS ( r = 0.27, p < 0.05) and state anxiety ( r = 0.25; p < 0.05), while the sensation of difficult evacuation directly correlated with the level of interleukin-1β ( r = 0.25; p < 0.05) and distress ( r = 0.27; p < 0.05) and inversely with the ratio of plasma serotonin to kynurenine ( r = –0.27; p < 0.05). The number of defecations per week and the presence of the need for additional straining did not show statistically significant correlations with any of the variables. The age of the subjects, duration of the disease, and cognitive indicators did not demonstrate a reliable correlation with the severity of FC symptoms. When assessing the gut microbiota composition, various correlations with FC symptoms were identified, the most significant of which was a direct correlation between the level of bacteria from the Ruminococcaceae family and the severity of abdominal bloating ( r = 0.39; p < 0.05). After randomization, the formed groups did not differ significantly in the assessed clinical, laboratory, and psychometric parameters, quality of life, age, and disease duration ( p > 0.05). During treatment, both groups showed significant improvement in all clinical parameters; however, Group FC-P showed a more pronounced reduction in abdominal pain ( p < 0.005) and sensation of incomplete evacuation ( p < 0.05). Only in Group FC-P was a significant improvement in cognitive function observed, with the total score and the results of the BACS subtests “Semantic and Phonemic Verbal Fluency”, “Digit Sequencing”, and “Tower of London” being significantly higher than in Group FC-PP ( p < 0.0001, p < 0.05, p < 0.05, and p < 0.0001, respectively). Quality of life, on the contrary, was significantly higher in Group FC-PP due to the indicators “Vitality” ( p < 0.05), “Emotional Role Functioning” ( p < 0.001), and “Mental Health” ( p < 0.05). A key difference in gut microbiota composition between the groups at the end of treatment was a change in the abundance of representatives of the order Lactobacillales , specifically the family Streptococcaceae , which increased in Group FC-P and decreased in Group FC-PP ( p < 0.05). In Group FC-PP, the number of representatives of the Ruminococcaceae family ( p < 0.05) and other bacteria capable of synthesizing short-chain fatty acids also increased significantly. No adverse events during therapy were reported in either group throughout the entire observation period. Conclusion. Disruption of the components of the “microbiota — gut — brain” axis in FC is closely associated with the symptoms of the disease. The efficacy of prucalopride as monotherapy and in combination with a multistrain probiotic regarding the symptoms of FC develops through influence on components of the “microbiota — gut — brain” axis not directly related to the pathogenesis of FC, while these approaches have divergent effects on cognitive function, quality of life, and the abundance of individual representatives of the phylum Firmicutes ( Bacillota ).
- 1 April 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (1)
Impact of Prucalopride and Multi-Strain Probiotic on Symptoms, Gut Microbiota Composition, Psychoemotional Status, Cognitive Function, and Quality of Life in Female Patients with Functional Constipation
Aim: to investigate the interrelationships between the severity of clinical symptoms, features of tryptophan metabolism, gut microbiota composition, quality of life, psychoemotional and cognitive status in female patients with functional constipation (FC), and to assess the ability of prucalopride as monotherapy and in combination with a multistrain probiotic to influence these parameters. Materials and methods. The study included 70 female patients with FC, who were randomized into two equal groups: patients of Group FC-P received prucalopride at a dose of 2 mg daily for 8 weeks, and patients of Group FC-PP received prucalopride at a similar dose together with a multi-strain probiotic ( Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus , not less than 1×10 9 CFU of each strain per capsule), 1 capsule 3 times a day for 8 weeks. At baseline, as well as after 2, 4, and 8 weeks, the groups were assessed for the number of defecations per week, stool form (Bristol Stool Scale, BSS), severity of abdominal bloating and abdominal pain against the background of bloating (Visual Analog Scale, VAS), as well as the presence of the need for additional straining, sensation of incomplete and difficult defecation. Before and after treatment, all subjects were assessed for levels of interleukin-1β, cortisol, brain-derived neurotrophic factor, tryptophan, kynurenine, kynurenic acid, serum and platelet serotonin, psychoemotional status (Spielberger — Hanin test, STAI), Hamilton Depression Rating Scale (HDRS), Four-Dimensional Symptom Questionnaire (4DSQ)), cognitive status (Brief Assessment of Cognition in Schizophrenia, BACS), quality of life (SF-36), and gut microbiota composition in stool samples (16S rRNA sequencing). Results. The study was completed by 34 patients in Group FC-P and 30 patients in Group FC-PP. Abdominal bloating directly correlated with the severity of somatization ( r = 0.25; p < 0.005) and inversely — with cortisol levels ( r = –0.29; p < 0.05). The severity of abdominal pain directly correlated with the levels of state and trait anxiety (STAI), distress, anxiety, and somatization (4DSQ) ( r = 0.32, p < 0.05; r = 0.28, p < 0.05; r = 0.31, p < 0.05; r = 0.26, p < 0.05; r = 0.35, p < 0.005, respectively) and inversely — with the indicators of vitality, emotional role functioning, and mental health (SF-36) ( r = –0.28, p < 0.05; r = –0.32, p < 0.01; r = –0.30, p < 0.05, respectively). Stool form type inversely correlated with the level of kynurenine ( r = –0.27; p < 0.05) and kynurenic acid ( r = –0.26; p < 0.05). The sensation of incomplete evacuation correlated with the severity of depression according to HDRS ( r = 0.27, p < 0.05) and state anxiety ( r = 0.25; p < 0.05), while the sensation of difficult evacuation directly correlated with the level of interleukin-1β ( r = 0.25; p < 0.05) and distress ( r = 0.27; p < 0.05) and inversely with the ratio of plasma serotonin to kynurenine ( r = –0.27; p < 0.05). The number of defecations per week and the presence of the need for additional straining did not show statistically significant correlations with any of the variables. The age of the subjects, duration of the disease, and cognitive indicators did not demonstrate a reliable correlation with the severity of FC symptoms. When assessing the gut microbiota composition, various correlations with FC symptoms were identified, the most significant of which was a direct correlation between the level of bacteria from the Ruminococcaceae family and the severity of abdominal bloating ( r = 0.39; p < 0.05). After randomization, the formed groups did not differ significantly in the assessed clinical, laboratory, and psychometric parameters, quality of life, age, and disease duration ( p > 0.05). During treatment, both groups showed significant improvement in all clinical parameters; however, Group FC-P showed a more pronounced reduction in abdominal pain ( p < 0.005) and sensation of incomplete evacuation ( p < 0.05). Only in Group FC-P was a significant improvement in cognitive function observed, with the total score and the results of the BACS subtests “Semantic and Phonemic Verbal Fluency”, “Digit Sequencing”, and “Tower of London” being significantly higher than in Group FC-PP ( p < 0.0001, p < 0.05, p < 0.05, and p < 0.0001, respectively). Quality of life, on the contrary, was significantly higher in Group FC-PP due to the indicators “Vitality” ( p < 0.05), “Emotional Role Functioning” ( p < 0.001), and “Mental Health” ( p < 0.05). A key difference in gut microbiota composition between the groups at the end of treatment was a change in the abundance of representatives of the order Lactobacillales , specifically the family Streptococcaceae , which increased in Group FC-P and decreased in Group FC-PP ( p < 0.05). In Group FC-PP, the number of representatives of the Ruminococcaceae family ( p < 0.05) and other bacteria capable of synthesizing short-chain fatty acids also increased significantly. No adverse events during therapy were reported in either group throughout the entire observation period. Conclusion. Disruption of the components of the “microbiota — gut — brain” axis in FC is closely associated with the symptoms of the disease. The efficacy of prucalopride as monotherapy and in combination with a multistrain probiotic regarding the symptoms of FC develops through influence on components of the “microbiota — gut — brain” axis not directly related to the pathogenesis of FC, while these approaches have divergent effects on cognitive function, quality of life, and the abundance of individual representatives of the phylum Firmicutes ( Bacillota ).
- 1 April 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (1)
Sacroliliitis as Debut of Crohn’s Disease
Aim: to present a clinical case of a patient with sacroiliitis preceding the development of the typical clinical picture of Crohn’s disease with colonic involvement. Key points. Patient K., 39 years old, was admitted to the clinic with complaints of pain in the sacral area lasting for 13 years, which was later joined by pain in the left iliac region, unstable stool (alternating diarrhea and constipation), hematochezia. Examination revealed signs of Crohn’s disease with colonic involvement and bilateral sacroiliitis. Therapy with adalimumab was initiated with a good clinical effect. Follow-up examination achieved endoscopic remission of the disease; however, residual MRI signs of bilateral sacroiliitis persist. Conclusion. This clinical case describes the outcome of adalimumab therapy in a patient with colonic Crohn’s disease, whose initial manifestation was the development of sacroiliitis. Adalimumab is well-established as an effective treatment for both Crohn’s disease and sacroiliitis, including when they occur concomitantly.
- 1 April 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (1)
Sacroliliitis as Debut of Crohn’s Disease
Aim: to present a clinical case of a patient with sacroiliitis preceding the development of the typical clinical picture of Crohn’s disease with colonic involvement. Key points. Patient K., 39 years old, was admitted to the clinic with complaints of pain in the sacral area lasting for 13 years, which was later joined by pain in the left iliac region, unstable stool (alternating diarrhea and constipation), hematochezia. Examination revealed signs of Crohn’s disease with colonic involvement and bilateral sacroiliitis. Therapy with adalimumab was initiated with a good clinical effect. Follow-up examination achieved endoscopic remission of the disease; however, residual MRI signs of bilateral sacroiliitis persist. Conclusion. This clinical case describes the outcome of adalimumab therapy in a patient with colonic Crohn’s disease, whose initial manifestation was the development of sacroiliitis. Adalimumab is well-established as an effective treatment for both Crohn’s disease and sacroiliitis, including when they occur concomitantly.
- Open Access
- 7 October 2025
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 35 (4) , 71-87
Gut Microbiota, Tryptophan Metabolism, Quality of Life, Psychoemotional and Cognitive Impairments in Functional Constipation
Aim: to investigate the relationship between tryptophan metabolism features, gut microbiota composition, systemic inflammation markers, cortisol levels, quality of life, and psychoemotional and cognitive status in female patients with functional constipation (FC).Materials and methods. The study included 64 female patients with FC and 26 age- and BMI-matched women without FC (p > 0.05). All participants underwent assessment of gut microbiota composition in stool samples (via 16S rRNA sequencing), health-related quality of life (SF-36), psychoemotional status (4DSQ, Spielberger — Hanin test, Hamilton scale), and cognitive function (BACS cognitive tests). Tryptophan metabolism was evaluated by measuring levels of interleukin-1β, cortisol, brain-derived neurotrophic factor (BDNF), tryptophan, kynurenine, kynurenic acid, and serum and platelet serotonin.Results. Compared to women without FC, female patients with FC had higher levels of cortisol (325 [266; 403] vs. 275[255; 304] nmol/L; p = 0.025), interleukin-1β (10.0 [9.2; 11.2] vs. 7.2 [6.5; 7.8] pg/mL; p < 0.001), and blood kynurenine (0.65 [0.54; 0.82] vs. 0.44 [0.35; 0.48] μg/mL; p < 0.001), as well as lower plasma serotonin levels (108 [85; 134] vs. 163 [117; 190] ng/mL; p < 0.001). No differences were found between groups in plasma tryptophan, BDNF, kynurenic acid, or platelet serotonin. Patients with FC exhibited more pronounced depression (Hamilton scale: 8 [6; 9] vs. 3 [2; 3] points; p < 0.001) and somatization (9 [7; 12] vs. 5 [3; 9] points; p < 0.001); lower cognitive function scores (50 [45; 54] vs. 54 [53; 56] points; p < 0.001), particularly in auditory-verbal memory (p < 0.001) and information processing speed (p < 0.001); and reduced quality of life (SF-36) in physical functioning (90 [83; 95] vs. 95 [95; 95] points; p < 0.001) and bodily pain (60 [50; 70] vs. 75 [56; 85] points; p < 0.001). Cortisol levels positively correlated with bodily pain (r = 0.379; p = 0.003), while interleukin-1β levels inversely correlated with bodily pain (r = –0.391; p = 0.002), physical functioning (r = –0.448; p < 0.001), and verbal memory (r = –0.252; p = 0.046), and positively correlated with depression (r = 0.311; p = 0.013) and somatization (r = 0.266; p = 0.035). Cortisol levels correlated positively with Oscillospira (r = 0.45; p = 0.01), while kynurenine levels correlated with Alistipes (r = 0.36; p = 0.04) abundance. Plasma serotonin positively correlated with Haemophilus (r = 0.37; p = 0.03) and inversely with Bacteroides plebeius (r = –0.40; p = 0.02) abundance. Physical functioning (SF-36) positively correlated with Lachnospiraceae NK4B4 group (r = 0.35; p = 0.04), while depression severity (4DSQ) inversely correlated with Alistipes abundance (r = –0.37; p = 0.03). Information processing speed is inversely correlated with abundance of Bacilli (r = –0.48; p = 0.004), Lactobacillales (r = –0.48; p = 0.004), Pasteurellales (r = –0.36; p = 0.03), Pasteurellaceae (r = –0.36; p = 0.03), Streptococcaceae (r = –0.47; p = 0.006), Haemophilus (r = –0.41; p = 0.02), and Streptococcus (r = –0.38; p = 0.02).Conclusion. The findings indicate that women with functional constipation exhibit altered tryptophan metabolism and gut microbiota dysbiosis, associated with depression, somatization, cognitive impairment, and reduced health-related quality of life.
- 7 October 2025
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 35 (4) , 71-87
Open AccessGut Microbiota, Tryptophan Metabolism, Quality of Life, Psychoemotional and Cognitive Impairments in Functional Constipation
Aim: to investigate the relationship between tryptophan metabolism features, gut microbiota composition, systemic inflammation markers, cortisol levels, quality of life, and psychoemotional and cognitive status in female patients with functional constipation (FC).Materials and methods. The study included 64 female patients with FC and 26 age- and BMI-matched women without FC (p > 0.05). All participants underwent assessment of gut microbiota composition in stool samples (via 16S rRNA sequencing), health-related quality of life (SF-36), psychoemotional status (4DSQ, Spielberger — Hanin test, Hamilton scale), and cognitive function (BACS cognitive tests). Tryptophan metabolism was evaluated by measuring levels of interleukin-1β, cortisol, brain-derived neurotrophic factor (BDNF), tryptophan, kynurenine, kynurenic acid, and serum and platelet serotonin.Results. Compared to women without FC, female patients with FC had higher levels of cortisol (325 [266; 403] vs. 275[255; 304] nmol/L; p = 0.025), interleukin-1β (10.0 [9.2; 11.2] vs. 7.2 [6.5; 7.8] pg/mL; p < 0.001), and blood kynurenine (0.65 [0.54; 0.82] vs. 0.44 [0.35; 0.48] μg/mL; p < 0.001), as well as lower plasma serotonin levels (108 [85; 134] vs. 163 [117; 190] ng/mL; p < 0.001). No differences were found between groups in plasma tryptophan, BDNF, kynurenic acid, or platelet serotonin. Patients with FC exhibited more pronounced depression (Hamilton scale: 8 [6; 9] vs. 3 [2; 3] points; p < 0.001) and somatization (9 [7; 12] vs. 5 [3; 9] points; p < 0.001); lower cognitive function scores (50 [45; 54] vs. 54 [53; 56] points; p < 0.001), particularly in auditory-verbal memory (p < 0.001) and information processing speed (p < 0.001); and reduced quality of life (SF-36) in physical functioning (90 [83; 95] vs. 95 [95; 95] points; p < 0.001) and bodily pain (60 [50; 70] vs. 75 [56; 85] points; p < 0.001). Cortisol levels positively correlated with bodily pain (r = 0.379; p = 0.003), while interleukin-1β levels inversely correlated with bodily pain (r = –0.391; p = 0.002), physical functioning (r = –0.448; p < 0.001), and verbal memory (r = –0.252; p = 0.046), and positively correlated with depression (r = 0.311; p = 0.013) and somatization (r = 0.266; p = 0.035). Cortisol levels correlated positively with Oscillospira (r = 0.45; p = 0.01), while kynurenine levels correlated with Alistipes (r = 0.36; p = 0.04) abundance. Plasma serotonin positively correlated with Haemophilus (r = 0.37; p = 0.03) and inversely with Bacteroides plebeius (r = –0.40; p = 0.02) abundance. Physical functioning (SF-36) positively correlated with Lachnospiraceae NK4B4 group (r = 0.35; p = 0.04), while depression severity (4DSQ) inversely correlated with Alistipes abundance (r = –0.37; p = 0.03). Information processing speed is inversely correlated with abundance of Bacilli (r = –0.48; p = 0.004), Lactobacillales (r = –0.48; p = 0.004), Pasteurellales (r = –0.36; p = 0.03), Pasteurellaceae (r = –0.36; p = 0.03), Streptococcaceae (r = –0.47; p = 0.006), Haemophilus (r = –0.41; p = 0.02), and Streptococcus (r = –0.38; p = 0.02).Conclusion. The findings indicate that women with functional constipation exhibit altered tryptophan metabolism and gut microbiota dysbiosis, associated with depression, somatization, cognitive impairment, and reduced health-related quality of life.
- Open Access
- 9 September 2024
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 34 (4) , 113-136
Methodological Guidelines of the Scientific Community for Human Microbiome Research (CHMR) and the Russian Gastroenterology Association (RGA) on the Use of Probiotics, Prebiotics, Synbiotics, Metabiotics and Functional Foods Enriched with Them for the Treatment and Prevention of Gastrointestinal Diseases in Adults and Children
Aim: to optimize outcomes of the treatment and prevention of gastrointestinal diseases in adults and children. Key points. The Methodological Guidelines contain sections on the terminology, classification, mechanisms of action, requirements for sale in the Russian Federation, requirements for proving the efficacy and safety of probiotics, prebiotics, synbiotics and metabiotics, as well as functional foods enriched with them. An overview of relevant data allowing to include these drugs and products in the treatment an d prevention of gastrointestinal diseases in adults and children is presented. Conclusion. The clinical efficacy of probiotics, prebiotics, synbiotics and metabiotics depends on the specificity and quantity of their components, the dosage form, the regimen and duration of treatment. Products and functional foods with proven efficacy and safety are recommended for the treatment and prevention of gastrointestinal diseases in adults and children.
- 9 September 2024
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 34 (4) , 113-136
Open AccessMethodological Guidelines of the Scientific Community for Human Microbiome Research (CHMR) and the Russian Gastroenterology Association (RGA) on the Use of Probiotics, Prebiotics, Synbiotics, Metabiotics and Functional Foods Enriched with Them for the Treatment and Prevention of Gastrointestinal Diseases in Adults and Children
Aim: to optimize outcomes of the treatment and prevention of gastrointestinal diseases in adults and children. Key points. The Methodological Guidelines contain sections on the terminology, classification, mechanisms of action, requirements for sale in the Russian Federation, requirements for proving the efficacy and safety of probiotics, prebiotics, synbiotics and metabiotics, as well as functional foods enriched with them. An overview of relevant data allowing to include these drugs and products in the treatment an d prevention of gastrointestinal diseases in adults and children is presented. Conclusion. The clinical efficacy of probiotics, prebiotics, synbiotics and metabiotics depends on the specificity and quantity of their components, the dosage form, the regimen and duration of treatment. Products and functional foods with proven efficacy and safety are recommended for the treatment and prevention of gastrointestinal diseases in adults and children.
- Open Access
- 18 February 2024
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 34 (2) , 14-34
Small Intestinal Bacterial Overgrowth in Various Specialties of Medical Practice (Literature Review and Expert Council Resolution)
Aim: to discuss current views on the clinical significance, diagnostic opportunities, and therapeutic approaches in the treatment of small intestinal bacterial overgrowth (SIBO) as an important component in the gut microbiota function assessment, to assess the awareness of physicians and the opportunities in the diagnosis and treatment of this disease in patients in the Federal districts of the Russian Federation, as well as to present the proceedings of the Expert Council held on December 16, 2023 in Moscow.Key points. SIBO is a common syndrome often associated with irritable bowel syndrome, liver cirrhosis, asthma, and congestive heart failure, being also a predictor of early death in the elderly. Today, in many regions of the Russian Federation, there are limitations for instrumental diagnosis of this disease — lack of awareness among doctors, unavailability of gas analyzers for diagnosing SIBO, lack of information about the need to diagnose SIBO in the standards of compulsory health insurance. Rifaximin is the first-line treatment due to the highest therapeutic efficacy. One of the ways to increase the efficacy of SIBO treatment is to include strain-specific probiotics in the treatment regimen. Saccharomyces boulardii CNCM I-745 is thought to be the most studied, promising probiotic. The review also presents statistical data on the issues in the diagnosis and treatment of SIBO in the regions of the Russian Federation.Conclusion. Optimization of approaches to the diagnosis and treatment of SIBO, the development of domestic gas analyzers, increasing the awareness of physicians in all regions of the Russian Federation, as well as the development and optimization of clinical recommendations appear to be necessary measures to increase the effectiveness of medical care, the duration and quality of life of the Russian population. These goals can be achieved within the framework of Federal programs under the supervision of specialized reference centers of the Ministry of Health of the Russian Federation.
- 18 February 2024
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 34 (2) , 14-34
Open AccessSmall Intestinal Bacterial Overgrowth in Various Specialties of Medical Practice (Literature Review and Expert Council Resolution)
Aim: to discuss current views on the clinical significance, diagnostic opportunities, and therapeutic approaches in the treatment of small intestinal bacterial overgrowth (SIBO) as an important component in the gut microbiota function assessment, to assess the awareness of physicians and the opportunities in the diagnosis and treatment of this disease in patients in the Federal districts of the Russian Federation, as well as to present the proceedings of the Expert Council held on December 16, 2023 in Moscow.Key points. SIBO is a common syndrome often associated with irritable bowel syndrome, liver cirrhosis, asthma, and congestive heart failure, being also a predictor of early death in the elderly. Today, in many regions of the Russian Federation, there are limitations for instrumental diagnosis of this disease — lack of awareness among doctors, unavailability of gas analyzers for diagnosing SIBO, lack of information about the need to diagnose SIBO in the standards of compulsory health insurance. Rifaximin is the first-line treatment due to the highest therapeutic efficacy. One of the ways to increase the efficacy of SIBO treatment is to include strain-specific probiotics in the treatment regimen. Saccharomyces boulardii CNCM I-745 is thought to be the most studied, promising probiotic. The review also presents statistical data on the issues in the diagnosis and treatment of SIBO in the regions of the Russian Federation.Conclusion. Optimization of approaches to the diagnosis and treatment of SIBO, the development of domestic gas analyzers, increasing the awareness of physicians in all regions of the Russian Federation, as well as the development and optimization of clinical recommendations appear to be necessary measures to increase the effectiveness of medical care, the duration and quality of life of the Russian population. These goals can be achieved within the framework of Federal programs under the supervision of specialized reference centers of the Ministry of Health of the Russian Federation.
- Open Access
- 22 August 2023
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 33 (3) , 85-119
Clinical Practice Guidelines of the Scientific Society for the Clinical Study of Human Microbiome, of the Russian Gastroenterological Association and the Russian Society for the Prevention of Noncommunicable Diseases on the Diagnosis and Treatment of Clostridioides difficile (C. difficile)-associated Disease in Adults
Аim: the clinical practice guidelines intended for gastroenterologists, internal medicine specialists, infectious disease specialists, general practitioners (family doctors), coloproctologists, surgeons and endoscopists present modern methods of diagnosis, prevention and treatment of C. difficile-associated disease.Key points. C. difficile-associated disease is a disease that develops when the diversity of the intestinal microbiota decreases and C. difficile excessively colonizes the colon, the toxins of which damage the intestinal muco-epithelial barrier, followed by the development of inflammation in the colon wall, with diarrhea being a characteristic clinical manifestation. The clinical presentation of the disease can vary from asymptomatic carriage, mild to moderate diarrhea that resolves on its own, to profuse watery diarrhea and pseudomembranous colitis with development of life-threatening complications. The diagnosis of C. difficile-associated disease is based on an assessment of the clinical presentation, medical history, an objective examination of the patient and laboratory stool tests. The disease severity is determined by clinical symptoms and laboratory findings. Additional diagnostic methods that are used according to indications and contribute to the assessment of severity include endoscopy of the colon and abdominal cavity imaging methods. Treatment should be initiated in cases of characteristic clinical presentation of C. difficile-associated disease and positive laboratory stool testing. The choice of drug and treatment regimen depends on the severity of the episode, the presence of complications, and whether the episode is initial, recurrent, or reinfection.Conclusion. Determination of target groups of patients for the diagnosis of clostridial infection is important in preventing overdiagnosis and subsequent unnecessary treatment. Timely diagnosis and treatment of C. difficile-associated disease help avoiding the development of life-threatening complications and improve the prognosis and quality of life of patients.
- 22 August 2023
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 33 (3) , 85-119
Open AccessClinical Practice Guidelines of the Scientific Society for the Clinical Study of Human Microbiome, of the Russian Gastroenterological Association and the Russian Society for the Prevention of Noncommunicable Diseases on the Diagnosis and Treatment of Clostridioides difficile (C. difficile)-associated Disease in Adults
Аim: the clinical practice guidelines intended for gastroenterologists, internal medicine specialists, infectious disease specialists, general practitioners (family doctors), coloproctologists, surgeons and endoscopists present modern methods of diagnosis, prevention and treatment of C. difficile-associated disease.Key points. C. difficile-associated disease is a disease that develops when the diversity of the intestinal microbiota decreases and C. difficile excessively colonizes the colon, the toxins of which damage the intestinal muco-epithelial barrier, followed by the development of inflammation in the colon wall, with diarrhea being a characteristic clinical manifestation. The clinical presentation of the disease can vary from asymptomatic carriage, mild to moderate diarrhea that resolves on its own, to profuse watery diarrhea and pseudomembranous colitis with development of life-threatening complications. The diagnosis of C. difficile-associated disease is based on an assessment of the clinical presentation, medical history, an objective examination of the patient and laboratory stool tests. The disease severity is determined by clinical symptoms and laboratory findings. Additional diagnostic methods that are used according to indications and contribute to the assessment of severity include endoscopy of the colon and abdominal cavity imaging methods. Treatment should be initiated in cases of characteristic clinical presentation of C. difficile-associated disease and positive laboratory stool testing. The choice of drug and treatment regimen depends on the severity of the episode, the presence of complications, and whether the episode is initial, recurrent, or reinfection.Conclusion. Determination of target groups of patients for the diagnosis of clostridial infection is important in preventing overdiagnosis and subsequent unnecessary treatment. Timely diagnosis and treatment of C. difficile-associated disease help avoiding the development of life-threatening complications and improve the prognosis and quality of life of patients.
- Open Access
- 28 April 2023
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 33 (2) , 19-33
Modern Approaches to the Diagnosis and treatment of Clostridioides difficile (C. difficile)-associated Disease in Adults (literature Review and Expert Council Resolution)
Aim: to review the modern approaches to the diagnosis and treatment ofC. difficile-associated disease in adults and present the resolution of the Expert Council held on March 25, 2023 in Moscow.General provisions.C. difficileis the most important nosocomial pathogen which spores are also commonly found in the environment. Microbiota impairment, primarily due to the use of antibacterial drugs, is a key stage in the development ofC. difficile-associated disease. A search for an infection should be carried out only in patients with diarrhea, and it is advisable to use at least 2 laboratory methods. The drug of choice for first-line treatment is vancomycin. If drug treatment is ineffective or the patient has recurrent clostridial infection, fecal microbiota transplantation should be considered. The probiotic strainSaccharomyces boulardii CNCM I-745has a direct inhibitory effect onC. difficiletoxin A, promotes normalization of the intestinal microbiota composition, and decreases the inflammatory reaction in colonic mucosa colonized with a toxigenic strain ofC. difficile.Conclusions. Addition of the probiotic strainSaccharomyces boulardii CNCM I-745to antibacterial therapy promotes both primary and secondary prevention ofC. difficile-associated disease.
- 28 April 2023
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 33 (2) , 19-33
Open AccessModern Approaches to the Diagnosis and treatment of Clostridioides difficile (C. difficile)-associated Disease in Adults (literature Review and Expert Council Resolution)
Aim: to review the modern approaches to the diagnosis and treatment ofC. difficile-associated disease in adults and present the resolution of the Expert Council held on March 25, 2023 in Moscow.General provisions.C. difficileis the most important nosocomial pathogen which spores are also commonly found in the environment. Microbiota impairment, primarily due to the use of antibacterial drugs, is a key stage in the development ofC. difficile-associated disease. A search for an infection should be carried out only in patients with diarrhea, and it is advisable to use at least 2 laboratory methods. The drug of choice for first-line treatment is vancomycin. If drug treatment is ineffective or the patient has recurrent clostridial infection, fecal microbiota transplantation should be considered. The probiotic strainSaccharomyces boulardii CNCM I-745has a direct inhibitory effect onC. difficiletoxin A, promotes normalization of the intestinal microbiota composition, and decreases the inflammatory reaction in colonic mucosa colonized with a toxigenic strain ofC. difficile.Conclusions. Addition of the probiotic strainSaccharomyces boulardii CNCM I-745to antibacterial therapy promotes both primary and secondary prevention ofC. difficile-associated disease.
- Open Access
- 30 December 2022
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 32 (6) , 7-19
Modern Approaches to H. pylori Eradication Therapy in Adults (Literature Review and Resolution of Experts Council)
Aim: to analyze current approaches to H. pylori eradication therapy in adults and present the materials of Experts Council held on December 9, 2022 in Moscow.General statements. H. pylori infection is the main etiological factor of gastritis, peptic ulcer, and gastric cancer. Eradication of H. pylori is recognized as a necessary measure to reduce the incidence of these diseases. The approaches to selecting an eradication regimen should be optimized to take into account epidemiological trends and achieve better treatment outcomes. The updated Maastricht VI Consensus Report presents the means to overcome the difficulties in selecting an approach to the treatment of H. pylori infection. However, eradication therapy remains challenging due to adverse events (primarily antibiotic-associated diarrhea), poor treatment tolerance and patient compliance. Eradication therapy can be optimized by supplementing treatment regimens with strain-specific probiotics that reduce adverse events, improve patient compliance and eradication rates, such as Saccharomyces boulardii CNCM I-745 strain with established efficacy.Conclusion. The inclusion of certain probiotics in eradication regimens improves treatment tolerance, reduces the risk of adverse events, improves patient compliance and eradication rates.
- 30 December 2022
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 32 (6) , 7-19
Open AccessModern Approaches to H. pylori Eradication Therapy in Adults (Literature Review and Resolution of Experts Council)
Aim: to analyze current approaches to H. pylori eradication therapy in adults and present the materials of Experts Council held on December 9, 2022 in Moscow.General statements. H. pylori infection is the main etiological factor of gastritis, peptic ulcer, and gastric cancer. Eradication of H. pylori is recognized as a necessary measure to reduce the incidence of these diseases. The approaches to selecting an eradication regimen should be optimized to take into account epidemiological trends and achieve better treatment outcomes. The updated Maastricht VI Consensus Report presents the means to overcome the difficulties in selecting an approach to the treatment of H. pylori infection. However, eradication therapy remains challenging due to adverse events (primarily antibiotic-associated diarrhea), poor treatment tolerance and patient compliance. Eradication therapy can be optimized by supplementing treatment regimens with strain-specific probiotics that reduce adverse events, improve patient compliance and eradication rates, such as Saccharomyces boulardii CNCM I-745 strain with established efficacy.Conclusion. The inclusion of certain probiotics in eradication regimens improves treatment tolerance, reduces the risk of adverse events, improves patient compliance and eradication rates.
- Open Access
- 30 December 2022
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 32 (6) , 72-93
Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for H. pylori Diagnostics and Treatment in Adults
Aim: bring to the attention of practitioners indications for anti-Helicobacter therapy, methods and procedure for diagnostics and eradication therapy ofН. pyloriinfection.Key points. Chronic gastritis caused byН. pyloriinfection, including asymptomatic persons, may be considered as an indication for eradication therapy of Н. pylori as etiological therapy and opportunistic screening for gastric cancer prevention. Indications, for obligatory anti-Helicobacter therapy include peptic ulcer, gastric MALT lymphoma, early gastric cancer (EGC) with endoscopic resection. H. pylori primary diagnostics methods include13C-urea breath test,H. pyloristool antigen lab test, rapid urease test and serological method. The serological method cannot be used after anti-Helicobacter therapy.In RussiaH. pyloristrains' resistance to clarithromycin does not exceed 15 % in most regional studies. The first line therapy forН. pyloriinfection eradication is the standard triple therapy including a proton pump inhibitor (PPI), clarithromycin and amoxicillin, enhanced with bismuthate tripotassium dicitrate. A classic four-component therapy based on bismuthate tripotassium dicitrate or quadrotherapy without bismuth drug products which includes PPI, amoxicillin, clarithromycin and metronidazole, may be used as alternative to the first line eradication therapy. The standard triple therapy may be prescribed for 14 days only in those regions, where it has been proven to be effective. Quadrotherapy with bismuthate tripotassium dicitrate is also used as main second line therapy in case of standard triple therapy, bismuth enhanced standard triple therapy or combined therapy failure. Another second line therapy includes PPI, levofloxacin and amoxicillin, to which a bismuth-containing drug product may be added. The third line therapy is selected individually based on previously used treatment settings.Conclusion. In each case ofH. pyloriinfection the decision for eradication therapy should be made, which is especially relevant as eradication ofH. pylorihas been recognized as an effective measure for the prevention of gastric cancer.
- 30 December 2022
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 32 (6) , 72-93
Open AccessClinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for H. pylori Diagnostics and Treatment in Adults
Aim: bring to the attention of practitioners indications for anti-Helicobacter therapy, methods and procedure for diagnostics and eradication therapy ofН. pyloriinfection.Key points. Chronic gastritis caused byН. pyloriinfection, including asymptomatic persons, may be considered as an indication for eradication therapy of Н. pylori as etiological therapy and opportunistic screening for gastric cancer prevention. Indications, for obligatory anti-Helicobacter therapy include peptic ulcer, gastric MALT lymphoma, early gastric cancer (EGC) with endoscopic resection. H. pylori primary diagnostics methods include13C-urea breath test,H. pyloristool antigen lab test, rapid urease test and serological method. The serological method cannot be used after anti-Helicobacter therapy.In RussiaH. pyloristrains' resistance to clarithromycin does not exceed 15 % in most regional studies. The first line therapy forН. pyloriinfection eradication is the standard triple therapy including a proton pump inhibitor (PPI), clarithromycin and amoxicillin, enhanced with bismuthate tripotassium dicitrate. A classic four-component therapy based on bismuthate tripotassium dicitrate or quadrotherapy without bismuth drug products which includes PPI, amoxicillin, clarithromycin and metronidazole, may be used as alternative to the first line eradication therapy. The standard triple therapy may be prescribed for 14 days only in those regions, where it has been proven to be effective. Quadrotherapy with bismuthate tripotassium dicitrate is also used as main second line therapy in case of standard triple therapy, bismuth enhanced standard triple therapy or combined therapy failure. Another second line therapy includes PPI, levofloxacin and amoxicillin, to which a bismuth-containing drug product may be added. The third line therapy is selected individually based on previously used treatment settings.Conclusion. In each case ofH. pyloriinfection the decision for eradication therapy should be made, which is especially relevant as eradication ofH. pylorihas been recognized as an effective measure for the prevention of gastric cancer.